ReviewDermatology and therapy2023
Healthcare Disparities in Atopic Dermatitis in Latin America: A Narrative Review.
Review in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Barriers to Accessing Pediatric Healthcare in Latin America: A Scoping Review.Journal of racial and ethnic health disparities · 2026Article
- Prevalence of allergic diseases and evaluation of total IgE and blood eosinophils as diagnostic biomarkers in Colombia, a tropical country.The World Allergy Organization journal · 2026Article
- The Patient Voice in Atopic Eczema Guidelines: How Do We Make it Standard Practice?The patient · 2026Review
- Burden, Treatment Patterns and Real-World Barriers to Prescribing Advanced Treatments in Adults with Atopic Dermatitis in Brazil and Colombia.Dermatology and therapy · 2026Article
- International Expert Consensus on Knowledge Gaps in Care for Dermatologic Disorders in Skin of Color.International journal of dermatology · 2026Article
- International Expert Consensus on Defining Skin of Color and Delivering Equitable Dermatologic Care.International journal of dermatology · 2026Article
- Sexual Health in Atopic Dermatitis: Impact of Skin Clinical Control.Clinical and translational allergy · 2025Article
- Moving beyond biology: the critical role of social and structural determinants in atopic dermatitis.International journal of dermatology · 2025Review
- Inflammatory Skin Disease in Latin America: Treatment Challenges and Opportunities.Journal of inflammation research · 2025Review
- Impact of socioeconomic factors on pediatric atopic dermatitis population.World journal of meta-analysis · 2025Article
- Patients' and Caregivers' Experiences Navigating the Burden of Atopic Dermatitis in Argentina.Medicina (Kaunas, Lithuania) · 2024Article
- Pharmacoequity in Allergy-Immunology: Disparities in Access to Medications for Allergic Diseases and Proposed Solutions in the United States and Globally.The journal of allergy and clinical immunology. In practice · 2024Review
- Ethnic and Racial Disparities in Clinical Manifestations of Atopic Dermatitis.Archives of internal medicine research · 2024Article
- Physician practices and attitudes towards atopic dermatitis in Latin America: A cross-sectional study.The World Allergy Organization journal · 2023Article
- Atopic Dermatitis in Latin America: Considerations on Epidemiology, Clinical and Laboratory Features, Ethnic/Racial Variations, and Therapeutic Management.Journal of clinical medicine · 2023Review
- The real-world burden of atopic dermatitis: MEASURE-AD results from Brazil, Mexico, and Argentina.Anais brasileiros de dermatologiaArticle
- Pruritus in atopic dermatitis: a cross-sectional study of adult patients from a tertiary university hospital in São Paulo, Brazil.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAtopic dermatitis (AD) is a chronic, pruritic skin disease caused by a mixture of genetic, immunological, and environmental factors, characterized by periods of inflammation and remission. In Latin America (LA), the prevalence of AD ranges up to 25% in children and 1-3% in adults. The natural history of the disease for most patients is that AD goes into remission in adolescence and adult life. Only 10-30% of patients continue to have symptoms of the disease in adulthood. There are patients (3-4%) who have the onset of AD during adolescence or after adulthood. Those with limited access to healthcare services, such as diagnosis and treatment, have increased difficulties coping with AD. Healthcare disparities are a complex topic that include social, political, racial/ethnic, and geographical factors. Publications about healthcare disparities in AD in LA are scarce. As a result, recognizing and resolving healthcare inequalities is critical to improving the treatment and quality of life (QoL) of individuals with AD.
methodsA panel of Latin American experts in dermatology and allergies was provided with a series of relevant questions to address before a multiday conference. During this conference, the entire group discussed and edited each narrative through numerous drafts and rounds of discussion until they reached a consensus.
resultsThis paper examines the barriers to equal access to care and recommends realistic actions to overcome them. Inadequate disease knowledge, cultural and linguistic barriers, stigmatization, maldistribution of resources, absence of local clinical practice guidelines, arduous patient journey, and limited consultation time were identified as causes of health inequality.
conclusionsAmong the suggested solutions are enhanced education for healthcare professionals, patients, and the general public, a focus on underprivileged communities, telemedicine and telementoring, translators, multidisciplinary teams, and local living clinical practice guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.